TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00964340

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
Study: NCT02083705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CC+SI
Description: Chest compression will be superimposed by sustained inflation during CPR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3:1 CPR
Description: CPR using 3:1 ratio (control group)
Study: NCT03834519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Oral tablets or oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral tablets
Study: NCT04132518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra
Description: Initial injection and optional 3 injections with Sculptra in Midface.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sculptra
Description: Initial injection and optional 3 injections with Sculptra in Midface.
Study: NCT02783040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study: NCT00789451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm vascular study
Description: Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
Study: NCT03527966

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 5cc Vivigen and local autograft
Description: The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Small kit rhBMP-2 with local autograft
Description: The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
Study: NCT05442320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)
Description: Toothpaste with 500 or 1000 ppm of fluoride

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodent Toothpaste (Ilirija d.d., Ljubljana, Slovenia)
Description: Toothpaste with 500 or 1000 ppm of fluoride
Study: NCT04101227

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Companion Diagnostic for Genetic Testing
Description: Companion Diagnostic for Genetic Testing

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Psychological Counseling
Description: Brief Psychological Counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Psychological Counseling
Description: Brief Psychological Counseling
Study: NCT00656799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
Study: NCT02783040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Study: NCT02924714

Intervention type: OTHER
Group type: OTHER
Intervention: Discontinuation of imatinib
Study: NCT05186701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio tape was applied with mechanical correction technique having I shaped with 50-100% tension for 72 hours on both shoulders in retracted position from the anterior aspect of the acromion to the spinous process of the 10th thoracic vertebra of the both shoulders.~Conventional Physical; Therapy:~Thermotherapy (hot pack) applied for 10 minutes. Myofacial release. Active isolated unilateral stretching of pectoralis minor muscle for 30 seconds (3 set × 3 reps/day).~Strengthening of shoulder retractors (lower trapezius and rhomboids). (3 set × 15 reps/day).~Participants were asked to do exercises at home on daily basis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Conventional Treatment: Hot pack, Myofascial Releaase, Stretching and Strengthening with Theraband
Study: NCT01636388

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic donor derived LMP specific cytotoxic T-lymphocyte
Description: LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
Study: NCT02233738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Description: Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Treatment Condition (CT)
Description: Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance.
Study: NCT03186079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiaojidaozhi Decoction
Description: Mixture of twelve Chinese herbal medicines granule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mixture of 10% Chinese herbal medicines granule and 90% artificial gum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fiberform
Description: Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fiberform
Description: Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Toilet training
Description: Toilet training has been considered a routine method in treatment of constipation
Study: NCT03423628

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Arm A: 35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks) Arm B: 30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).~\*\*Arm B has now closed to recruitment\*\* Arm C: 60 Gy of intensity-modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1390
Description: AZD1390 Administered in 3 Cycles depending on arm:~Cycle 0 (arms A and C): 1 dose prior to Radiation Therapy. For optional food effect assessment in Arm A, 2 doses prior to RT under both fed and fasted conditions. \*Note: the optional food effect assessment is currently not open to recruitment\*.~Cycle 1 (all arms): Intermittent or continuous dosing during Radiation Therapy (except for first 2 cohorts of Arm A).~Cycle 2 (arms A and C): 2 weeks adjuvant treatment after Radiation Therapy.
Study: NCT00795522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
Study: NCT02478801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amino acids intake
Description: amino acids intakes will be varied at 0.2-2.8 g/kg/day
Study: NCT03808051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiological-based cord clamping
Description: See Arm description.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Time-based cord clamping
Description: See Arm description.
Study: NCT00937157

Intervention type: DRUG
Group type: OTHER
Intervention: Copaxone
Description: 12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
Study: NCT04246294

Intervention type: DEVICE
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP is golden standard treatment for moderate-to-severe sleep apnea with high compliance, effectiveness, and cost-effectiveness.~There will be no interference with standard care.
Study: NCT02225990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group, Sub-Acute
Description: For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group, Chronic
Description: For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Sub-Acute
Description: This group will receive standard of care stroke rehabilitation therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care, Chronic
Description: This group will receive standard of care stroke rehabilitation therapy.
Study: NCT02943720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT
Description: Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT
Description: Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02969304

Intervention type: DRUG
Intervention: dimethyl fumarate
Description: Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants \>18 years of age with an MS diagnosis who are prescribed dimethyl fumarate

Intervention type: DRUG
Intervention: dimethyl fumarate
Description: Off-Label Use: All participants \<18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants \>18 years of age with an MS diagnosis who are prescribed dimethyl fumarate
Study: NCT03884218

Intervention type: OTHER
Group type: OTHER
Intervention: Infra red thermal imaging
Description: thermal image using a non-touch, non-ionising, thermal camera system
Study: NCT00558025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Extended Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Immediate Release
Study: NCT02646280

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive rehabilitation
Description: Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
Study: NCT00649701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Text-Based Prevention Web Page
Description: A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Morning After
Description: A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking About HIV
Description: A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Both Videos
Description: Morning After and Talking About HIV videos
Study: NCT01846507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
Study: NCT02187250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: roflumilast
Study: NCT01072812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posiphen® tartrate capsules
Description: Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
Study: NCT01980914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPro2 glucose sensor attachment
Description: At the same time the glucose sensor is started, a trained research nurse will connect the patient to an Icentia CardioSTAT, a continuous ambulatory ECG cardiac monitor.
Study: NCT02946645

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Bite (orthotic/sub-lingual)
Description: Bite is a device which simulates a set of properly positioned teeth

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Physiotherapy
Description: Mandibular Stabilisation Exercises~1. Place knuckle of index finger between top and bottom teeth.~2. Remove it, keeping the teeth separated one-knuckle apart.~3. Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No interventions.
Study: NCT01121887

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge.
Study: NCT00549523

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing 0 mg bid (placebo)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose
Description: Capsules containing 400 mg bid of L. frutescens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid Dose
Description: Capsules containing 800 mg bid of L. frutescens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose
Description: Capsules containing 1200 mg bid of L. frutescens.
Study: NCT04464122

Intervention type: DRUG
Intervention: Somatostatin analog; chemotherapy
Description: According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.
Study: NCT04035928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D digital scanning for maxillofacial prosthetics
Description: The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
Study: NCT02551731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: 20 or 40 mg/kg/day BID
Study: NCT02950454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: 1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous moderate exercise
Description: 20 min at 60-70% heart rate max on cycle ergometer
Study: NCT03231033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
Study: NCT03992820

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS machine
Description: The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: EMLA cream
Description: The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration.
Study: NCT00837304

Intervention type: DEVICE
Intervention: PillCam Colon Capsule
Description: PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.

Intervention type: PROCEDURE
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
Study: NCT01961323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP\<140 and DBP \<90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
Study: NCT03791476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhC1INH
Description: C1 esterase inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline solution
Study: NCT04123054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mobile App
Description: Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile App + Basal-Bolus Optimization Algorithm
Description: Participants will use the mobile app to log their daily basal dose and calculate their meal doses by entering their sensor glucose value (and amount of meal carbohydrates if applicable) using the built-in bolus calculator. In addition, participants will receive weekly app notifications with personalized recommendations for insulin parameter adjustments made by the optimization algorithm.